Syra Health Corp.

Company Overview

Business Model: SYRA HEALTH CORP. is an integrated healthcare solutions company that provides prevention-focused, accessible, and affordable solutions to government and commercial healthcare organizations. The Company delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. Revenue is primarily generated through contracts for medical staffing, data analytics, reporting, training, and technology development and maintenance.

Market Position: The Company operates in rapidly growing healthcare markets. The U.S. behavioral health market was valued at $151.7 billion in 2023 (CAGR of 3.7% from 2024-2032), the U.S. population health management market at $25.0 billion in 2022 (CAGR of 19.5% from 2022-2030), the U.S. digital health market at $81.17 billion in 2023 (CAGR of 19.5% from 2024-2030), the U.S. health education market at $110 billion in 2023 (CAGR of 11.0% to $280.6 billion by 2033), and the U.S. healthcare staffing market at $36.9 billion in 2022 (CAGR of 6.93% from 2023-2030). SYRA HEALTH CORP. faces substantial competition from healthcare consulting service providers, healthcare payment accuracy companies, data product and analytics solution providers, and even some of its own customers who provide similar solutions internally.

Recent Strategic Developments: SYRA HEALTH CORP. launched Syrenity, a comprehensive mental health application utilizing artificial intelligence, in the fourth quarter of 2024. The Company is developing additional digital health solutions, including SyraBot (an AI-powered chatbot) and CarePlus (an electronic medical records solution). Strategic growth initiatives include expanding operations to new metropolitan and rural areas, growing sales and business development teams, opening new offices, and investing in partnerships with subject matter experts. The Company also considers acquisitions to strengthen existing service offerings or introduce new ones. Its government solutions business line targets federal agencies such as the United States Department of Health and Human Services, the Centers for Disease Control and Prevention, the National Institutes of Health, the National Aeronautics and Space Administration, and the United States Department of Defense.

Geographic Footprint: SYRA HEALTH CORP.'s corporate headquarters are located in Carmel, Indiana. The Company aims to expand its operations to other metropolitan and rural areas across the country and plans to open offices in multiple geographical locations to support sales and business development efforts.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 34.4% (2025) vs. 20.7% (2024)
• Operating Margin: -12.5% (2025) vs. -47.1% (2024)
• Net Margin: -12.4% (2025) vs. -47.1% (2024)

Investment in Growth:

• R&D Expenditure: $0.07 million (1.0% of revenue) in 2025 vs. $0.59 million (7.4% of revenue) in 2024.
• Capital Expenditures: $0.0001 million in 2025 vs. $0.01 million in 2024.
• Strategic Investments: Continued development of the Syrenity application for Behavioral and Mental Health services.

Business Segment Analysis

Healthcare Services (Overall Segment)

Financial Performance:

• Revenue: $7.23 million (-9.3% YoY)
• Operating Margin: -12.5% (improved from -47.1% in 2024)
• Key Growth Drivers: The Company's overall strategy focuses on providing customized, comprehensive end-to-end solutions for public and private healthcare sectors, expanding operations, and investing in partnerships. The shift in service mix towards project-based population health services contributed to improved gross margins.

Sub-segment Breakdown:

• Healthcare Workforce:
  • Revenue: $1.90 million (-67.7% YoY)
  • Key Growth Drivers: Decrease attributed to fewer new customer acquisitions and lower renewal value on the FSSA (NeuroDiagnostic Institute) contract, which runs through June 2026 with a ceiling value of approximately $1.48 million.
• Population Health:
  • Revenue: $5.32 million (+157.2% YoY)
  • Key Growth Drivers: Increase due to additional services provided to state health departments and other customers. This segment carries better margins compared to healthcare workforce services.
• Behavioral and Mental Health:
  • Revenue: $0 million (-100% YoY from $16,845 in 2024)
  • Product Portfolio: Syrenity, a comprehensive mental health application, was launched in the fourth quarter of 2024. It is designed for preventative care and interventions, utilizing AI-driven user diaries, targeted assignments, education, symptom monitoring, and timely interventions like cognitive behavioral therapy and mindfulness techniques. It also enables virtual consultations with licensed mental health professionals.
• Digital Health:
  • Revenue: $0 million (from $369,000 in 2024)
  • Product Portfolio: The Company is developing SyraBot (an AI-powered chatbot for patient connectivity and engagement) and CarePlus (an electronic medical records solution for small to mid-sized healthcare organizations).
• Health Education Services:
  • Revenue: $0 million (from $40,000 in 2024)
  • Product Portfolio: Provides medical education solutions to pharmaceutical and medical device manufacturers, biotechnology companies, payers, large employers, academic institutions, and government agencies. Content development drives client organizational and strategic brand goals, utilizing omnichannel delivery approaches (in-person, virtual, hybrid) and AI tools for real-time information.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported.
• Dividend Payments: SYRA HEALTH CORP. has never paid or declared any cash dividends and does not anticipate paying any in the foreseeable future, intending to retain all available funds for business development and expansion.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No authorized programs or amounts for future capital returns were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $1.61 million (as of December 31, 2025)
• Total Debt: $0.12 million (Notes payable as of December 31, 2025)
• Net Cash Position: $1.49 million (as of December 31, 2025)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Insurance notes payable totaling $0.12 million are due through July 2026, with interest rates of 9.70% and 10.30%.

Cash Flow Generation:

• Operating Cash Flow: -$0.45 million (2025) vs. -$2.93 million (2024), an improvement primarily due to reduced expenses and better working capital management.
• Free Cash Flow: -$0.45 million (2025) (Operating Cash Flow of -$0.45 million - Capital Expenditures of $0.0001 million).

Operational Excellence

Production & Service Model: SYRA HEALTH CORP. delivers integrated healthcare solutions through end-to-end capabilities across its service lines. The Company utilizes agile implementation staffing methodologies for its healthcare workforce solutions to efficiently expand client clinical personnel. Its operational philosophy emphasizes prevention-focused, accessible, and affordable solutions to improve health outcomes.

Supply Chain Architecture: The Company relies on independent content providers for the development of health education and scientific content resources. Its operations are vulnerable to interruptions and damage from various sources, including power loss, telecommunications failures, software/hardware errors, and cyberattacks, some of which are outsourced to third-party hosting providers.

Key Suppliers & Partners:

• Office Lease: STVentures, LLC (an entity beneficially owned by the principal owners and management team of SYRA HEALTH CORP. and their affiliates).
• IT Services: RAD CUBE LLC (an entity beneficially owned by the principal owners and management team of SYRA HEALTH CORP. and their affiliates).
• Recruitment and HR Services: NLogix IT Services Private Limited and SKL Demand Private Limited (entities beneficially owned by the principal owners and management team of SYRA HEALTH CORP. and their affiliates).

Facility Network:

• Corporate Headquarters: 1119 Keystone Way N. #201 Carmel, IN 46032, leased from STVentures, LLC. The lease was amended in July 2025, providing for a base monthly rent of $5,580 from September 1, 2025, through May 31, 2026.
• Research & Development: R&D expenses are primarily consulting expenses incurred to develop technology-based solutions, such as the Syrenity application.

Operational Metrics: No specific operational metrics beyond financial performance were disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: SYRA HEALTH CORP. aims to become a leader in healthcare solutions by providing customized and comprehensive end-to-end solutions to public and private healthcare sectors. The Company plans to expand its operations to other metropolitan and rural areas, replicate projects with similar customers across the country through rapid growth of sales and business development teams, and open offices in multiple geographical locations. It also intends to invest in partnerships with subject matter experts to enhance service lines.

Distribution Channels: For health education services, the Company utilizes omnichannel delivery approaches, including in-person, virtual, and hybrid arrangements, with deliverables in traditional print and electronic formats. Digital platforms are being developed to connect physicians, patients, caregivers, payers, and other stakeholders.

Customer Portfolio:

• Customer Concentration:
  • For the year ended December 31, 2025, the Indiana Family and Social Services Administration (FSSA) accounted for approximately 35% of total revenues and 8% of accounts receivable.
  • For the year ended December 31, 2025, Humana, Inc. accounted for approximately 37% of total revenues and 74% of accounts receivable.
  • As of December 31, 2025, Coordinated Care Corporation (doing business as Managed Health Services) owed 11% of the Company’s accounts receivable.
  • For the year ended December 31, 2024, FSSA accounted for approximately 61% of total revenues and 56% of accounts receivable.
• Strategic Partnerships: The Company intends to invest in partnerships with subject matter experts.

Geographic Revenue Distribution: The Company primarily provides services to state health and social service agencies and universities across the country. No specific percentage breakdown by region or country was provided.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The healthcare services markets are characterized by significant competition and increasing standardization, which can facilitate new market entrants. Key drivers for the Company's service lines include rising awareness of mental health issues, increased access to care, growing adoption of telehealth, demand for healthcare IT services, an aging population, and technological advancements (e-learning, AI, VR).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: SYRA HEALTH CORP. faces competition from healthcare consulting service providers, healthcare payment accuracy companies, providers of other data products and data analytics solutions (including healthcare risk adjustment, quality, economic statistics), and certain customers who provide similar solutions internally.

Emerging Competitive Threats: The increasing standardization of certain healthcare services makes it easier for new companies to enter these markets. The Company also faces risks from companies in adjacent product or service areas launching competitive offerings.

Competitive Response Strategy: The Company's strategy involves continuously upgrading existing solutions and developing new ones to respond to regulatory developments and customer demands. It aims to provide high-quality, innovative products at competitive prices and achieve market acceptance for new offerings through substantial marketing efforts.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The Company faces significant competition, including from larger entities with greater resources. Its ability to retain existing customers and attract new ones depends on providing efficient and cost-effective solutions, responding to pricing pressures, and continuously upgrading/introducing new solutions. Economic downturns or volatility can reduce demand for solutions, increase competitive pricing pressure, and lead to contract terminations or non-renewals by government clients. Demand for staffing services is sensitive to economic activity.
• Technology Disruption: The Company's use and development of artificial intelligence products (Syrenity, SyraBot) may lead to unexpected outcomes, reputational harm, and legal/regulatory risks in a rapidly developing field. Failure to update and improve existing solutions or develop new ones in a timely manner could lead to obsolescence and loss of market share.
• Customer Concentration: For the year ended December 31, 2025, FSSA accounted for approximately 35% of revenues and Humana, Inc. accounted for approximately 37% of revenues. The loss of one or more major customers or a substantial decrease in demand could materially adversely affect the business.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Reliance on independent content providers for health education and scientific content resources exposes the Company to risks if these providers fail to perform adequately or comply with laws/regulations.
• Poor Service/System Errors: Some solutions provide information to healthcare professionals for patient care, and errors or failures could lead to claims, litigation, and reputational harm, despite contractual liability disclaimers.
• IT System Breaches: The Company relies on information systems and secure transmission/storage of sensitive information (PHI, PII, financial data). Breaches or failures of IT systems (internal or outsourced) could lead to liability, reputational harm, and significant costs.
• Reliance on Internet Infrastructure: The Company's ability to deliver solutions depends on Internet infrastructure, bandwidth providers, data center providers, and its own systems. Failures or interruptions could expose it to litigation and negatively impact customer relationships.
• Data Permissions: Failure by customers to obtain proper permissions or provide accurate information may limit or prevent the Company's use of data, leading to claims or impaired services. Privacy concerns could also damage reputation.
• Recruitment and Retention: The Company's success depends on its ability to recruit and retain skilled management, technical personnel, and quality healthcare professionals, which is challenging due to intense competition and shortages.
• Contract Underpricing/Cost Overruns: Most grant writing service contracts are fee-for-service or fixed-fee, exposing the Company to risks if contracts are underpriced, costs overrun, or change orders are delayed.
• Demands of New Services/Clients: Expanding into new services, capabilities, and geographic locations places substantial demands on management, personnel, and systems, potentially increasing operating risks.

Financial & Regulatory Risks

• Market & Financial Risks: The Company has incurred recurring losses and has an accumulated deficit, raising substantial doubt about its ability to continue as a going concern without additional capital. It will require substantial additional funding, and there is no guarantee such financing will be available on favorable terms or at all. Unstable market and economic conditions could make financing more difficult and costly.
• Regulatory & Compliance Risks: The business is heavily regulated by federal and state entities. Non-compliance with procurement laws for government contracts could lead to sanctions, penalties, or contract termination. Healthcare regulations (Anti-Kickback Statute, False Claims Act, FCPA, HIPAA, state data privacy laws) are complex and subject to interpretation, with potential for investigations, fines, and civil/criminal penalties. The federal government pausing or terminating spending programs could negatively affect revenue.

Geopolitical & External Risks

• Geopolitical Exposure: The global credit and financial markets have experienced volatility and disruptions, including those from military conflicts (e.g., Russia-Ukraine), terrorism, or other geopolitical events, which could adversely affect the Company's business, financial condition, and stock price.

Innovation & Technology Leadership

Research & Development Focus:

• Core Technology Areas: SYRA HEALTH CORP. focuses on integrating artificial intelligence into its healthcare solutions.
• Innovation Pipeline:
  • Syrenity: A proprietary behavioral and mental health application designed for preventative care and interventions, utilizing an AI-driven user diary, targeted assignments, education, symptom monitoring, and timely interventions (e.g., cognitive behavioral therapy, mindfulness techniques). It also facilitates virtual consultations with licensed mental health professionals. Launched in Q4 2024.
  • SyraBot: An AI-powered chatbot intended to foster connectivity and engagement throughout individuals’ care journeys, offering round-the-clock access to information via customer support.
  • CarePlus: An electronic medical records solution designed for small to mid-sized healthcare organizations.

Intellectual Property Portfolio: The Company relies on a combination of trade secret, copyright, and trademark laws, patents, license agreements, confidentiality procedures, nondisclosure agreements, and technical measures to protect its intellectual property.

Technology Partnerships: The Company intends to invest in partnerships with subject matter experts to further enhance its service lines and provide real-world insights. RAD CUBE LLC, a related party, provides outsourced IT services.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Gregory R. Alexander was appointed CEO effective January 5, 2026. Priya Prasad served as interim CEO from June 16, 2025, following the termination of former CEO Deepika Vuppalanchi on June 13, 2025. Sandeep Allam, former Executive Chairman and President, passed away, leading to the conversion of his Class B common stock to Class A common stock on January 15, 2025.

Board Composition: A new director was appointed to the Board of Directors on August 13, 2025. No further details on board independence, expertise areas, or committee structure were disclosed.

Human Capital Strategy

Workforce Composition: As of March 4, 2026, SYRA HEALTH CORP. employed 38 full-time employees and 51 part-time employees.

Talent Management:

• Acquisition & Retention: The Company's success depends on its ability to identify, attract, hire, and retain highly qualified personnel, including skilled management, scientific personnel, and healthcare professionals. Competition for qualified personnel in the healthcare services industry is intense.
• Employee Value Proposition: The Company provides postretirement benefits through a 401(k) plan, matching 100% of employee contributions up to 2%.

Diversity & Development: No specific diversity metrics or development programs were disclosed.

Business Cyclicality & Seasonality

Demand Patterns: Demand for the Company's staffing services is sensitive to changes in economic activity. When hospital admissions decrease during economic downturns or periods of high inflation, the demand for temporary healthcare professionals typically declines as permanent staff work more hours. The Company's revenue is also heavily dependent on state, local, and county government budgets, which can be affected by federal spending programs.

Planning & Forecasting: The Company's operating plan may change due to unknown factors, and it may need additional funds sooner than planned. Delays in new contract awards or cancellations of requests for proposals due to government spending reviews are expected to negatively affect revenue in the near term.

Regulatory Environment & Compliance

Regulatory Framework: SYRA HEALTH CORP. operates in a heavily regulated environment, subject to oversight by governmental entities in the U.S.

• Industry-Specific Regulations: The Company is subject to federal and state healthcare laws and regulations, including the Anti-Kickback Statute and False Claims Act, which prevent fraud and abuse in the healthcare industry. It also complies with the U.S. Foreign Corrupt Practices Act (FCPA) for international interactions.
• International Compliance: Not explicitly detailed beyond FCPA.

Trade & Export Controls: The Company is subject to trade restrictions and export controls, which can impact business limitations and require compliance.

Legal Proceedings: A wrongful termination lawsuit filed by a former employee in January 2024 was settled on January 15, 2025, with no material impact to the Company. The Company may be a party to other legal and regulatory proceedings in the ordinary course of business.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company has incurred net operating losses (NOLs) since inception and has not recorded a provision for income taxes. A full valuation allowance is provided against its net deferred tax assets due to uncertainty of realization.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The Company is subject to U.S. federal, state, and local taxes. Recent changes in U.S. tax laws, including the Tax Cuts and Jobs Act of 2017, the CARES Act, and the Inflation Reduction Act of 2022 (which includes a 15% minimum tax on global adjusted financial statement income and a 1% excise tax on share repurchases), may affect future financial results.

Insurance & Risk Transfer

Risk Management Framework: SYRA HEALTH CORP. maintains liability insurance coverage, including coverage for cyber-liability, to mitigate risks associated with potential claims arising from negligence, errors, mistakes, security breaches, or faulty clinical decisions resulting from the use of its solutions. However, there is no assurance that coverage will be adequate or available on acceptable terms.